NovaBay Pharmaceuticals, Inc. Reports First Quarter 2009 Financi...(ts are forward-looking statements. Forw...),Health

Date:5/18/2009

ts, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to: the risk that milestones and net sales may not be achieved under the Galderma agreement; the risk that NovaBay may incur unexpected charges or need to or determine to engage in research and development not previously planned, which will cause NovaBay's research and development expenses to be greater than it expects; risks and uncertainties relating to difficulties or delays in discovery, development, testing, production and marketing of the company's product candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates; the uncertainty of patent protection for the company's intellectual property or trade secrets; the company's ability to obtain additional financing as necessary; results obtained in animal models may not be obtained in humans; and the risk of unexpected delays in the regulatory process which may delay the commencement or completion of clinical trials. Other risks relating to NovaBay and Aganocide(R) compounds, including risks that could cause actual results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's Annual Report on Form 10-K for the period ended December 31, 2008, under the caption "Risk Factors" in Item 1A of Part I of that report, filed with the Securities and Exchange Commission on March 31, 2009. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.

    Contact:

    NovaBay 
'/>"/>
SOURCE  NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 
Related medicine news :

1. NovaBay Pharmaceuticals Scientific Advisor Receives American Chemical Societys Highest Award
2. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
3. NovaBay announces third quarter 2007 financial results
4. NovaBay Pharmaceuticals Closes Initial Public Offering of Common Stock
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
7. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
8. Jazz Pharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
9. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
10. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Receives Notice of De-Listing of Its Securities for Failure to Regain Compliance with Continued Listing Requirements